Patrys's SM6 bound for new myeloma trial
Patrys (ASX:PAB) has announced that its anticancer antibody PAT-SM6 will be trialled in combination with Onyx Pharmaceuticals’ carfilzomib for multiple myeloma patients.
The investigator-sponsored trial will be led by Dr Hermann Einsele, director of the Department of Medicine II at the University of Würzburg in Germany. It is being funded by Onyx, an Amgen subsidiary.
The study will evaluate the combination use of PAT-SM6 and proteasome inhibitor carfilzomib (marketed by Onyx as Kyprolis) in patients with relapsed and refractory multiple myeloma.
According to Patrys, the fact that PAT-SM6 has so far demonstrated a lack of serious side-effects in treated patients during the ongoing Phase I/IIa trial suggests it can be administered safely with carfilzomib, and the combination may improve on current multiple myeloma treatments.
The company separately announced it has been granted a second US patent for PAT-LM1, another anticancer antibody in preclinical development.
This new patent covers “neoplasm-specific antibodies and uses thereof”. It is the second US patent covering the antibody - the first was granted in mid-2010. Patrys also has a New Zealand patent covering the potential use of the antibody for the treatment or prevention of metastasis.
Patrys (ASX:PAB) shares were trading 66% higher at $0.088 as of around 1 pm on Monday.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
